Adaptive Radiation Boost for Rectal Cancer (ARBOR) - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • By

  • September 4, 2026

  • 3 min

Share

Objective:

To determine the safety and efficacy of additional adaptive radiation therapy following standard chemoradiation treatment in patients with rectal cancer.

Approach:
  • Standard Treatment: Participants will first receive standard treatment: radiation (45 Gy in 25 sessions) along with capecitabine chemotherapy.
  • Adaptive Radiation Therapy: Extra radiation will be administered using MRI scans every two weeks to adjust treatment based on tumor response, utilizing a small balloon to protect healthy tissue.
  • Additional Chemotherapy: Participants will receive additional chemotherapy (such as FOLFOX) for four months after the adaptive radiation therapy.
Key Findings:
  • The trial aims to target aggressive cancer cells more accurately.
  • The approach seeks to minimize side effects during treatment.
Limitations:
  • Exclusion of patients previously treated for rectal cancer.
  • Exclusion of patients with rectal cancer involving the anal canal.
  • Participants must not be pregnant or breastfeeding.
Conclusion:

The ARBOR trial is designed to explore innovative radiation therapy techniques to enhance treatment for rectal cancer.

Sources:

Original Source(s)

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

  • by

  • September 4, 2026

Related Content

Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min
Therapy-induced immunoediting and the evolution of cancer immune escape

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min